Observations on the classification of the inflammatory myopathies

Presse Medicale

Volumn 40, Issue 4, 2011, Pages

  Hilton Jones, David ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; STEROID;

ANTIBODY DETECTION; CLINICAL FEATURE; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ELECTROMYOGRAPHY; GOLD STANDARD; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; MYOSITIS; POLYMYOSITIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TREATMENT PLANNING;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MUSCLES; MYOSITIS; PROGNOSIS;

EID: 79953767937     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.10.035     Document Type: Short Survey

References (41)

1. Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med 2011.
2. Askanas V., Engel W.K., Nogalska A. Inclusion-body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation: mini-symposium: protein aggregate myopathies. Brain Pathol 2009, 19:493-506.
3. Engel W.K., Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 2006, 66:S20-S29.
4. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
5. Eaton L.M. The perspective of neurology in regard to polymyositis; a study of 41 cases. Neurology 1954, 4:245-263.
6. Walton J., Adams R. Polymyositis 1958, Livingstone, Edinburgh and London.
7. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407.
8. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
9. Bohan A., Peter J.B., Bowman R.L., Pearson C.M. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977, 56:255-286.
10. Sato T., Walker D.L., Peters H.A., Reese H.H., Chou S.M. Myxovirus-like inclusion bodies in chronic polymyositis: Electron microscopic and viral studies. Trans Am Neurol Assoc 1969, 94:339-341.
11. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., et al. Inclusion-body myositis and myopathies. Ann Neurol 1995, 38:705-713.
12. Benveniste O., Hilton-Jones D. International workshop on inclusion-body myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010, 20:414-421.
13. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M.G. Inclusion-body myositis. MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disor 2010, 20:142-147.
14. Chahin N., Engel A.G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008, 70:418-424.
15. Engel A.G., Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987, 505:326-332.
16. Engel A.G., Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion-body myositis. Ann Neurol 1984, 16:209-215.
17. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988, 23:493-499.
18. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988, 23:168-173.
19. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986, 19:112-125.
20. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T-cells. Ann Neurol 1984, 16:193-208.
21. Van der Meulen M.F.G., Bronner I.M., Hoogendijk J.E., Burger H., van Venrooij W.J., Voskuyl A.E., et al. Polymyositis: an overdiagnosed entity. Neurology 2003, 61:316-321.
22. Miller F.W., Rider L.G., Plotz P.H., Isenberg D.A., Oddis C.V., et al. Diagnostic criteria for polymyositis and dermatomyositis [3]. Lancet 2003, 362:1762-1763.
23. Targoff I.N. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheumatol Rep 2002, 4:434-441.
24. Targoff I.N., Miller F.W., Medsger T.A., Oddis C.V. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997, 9:527-535.
25. Miller F.W. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. J Am Med Assoc 1993, 270:1846-1849.
26. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
27. Hengstman G.J.D., Van Engelen B.G.M., Van Venrooij W.J. Myositis-specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004, 16:692-699.
28. Hengstman G.J.D., Brouwer R., Egberts W.T., Seelig H.P., Jongen P.J., van Venrooij W.J., et al. Clinical and serological characteristics of 125 Dutch myositis patients: myositis-specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002, 249(1):69-75.
29. Hengstman G.J.D., van Engelen B.G., Vree Egberts W.T., van Venrooij W.J. Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 2001, 13:476-482.
30. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senécal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005, 84:231-249.
31. Hengstman G.J.D., ter Laak H.J., Vree Egberts W.T., Lundberg I.E., Moutsopoulos H.M., Vencovsky J., et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006, 65:1635-1638.
32. Dmitri D., Andre C., Roucoules J., Hosseini H., Humbel R.L., Authier F.J. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007, 35:389-395.
33. Suzuki S., Satoh T., Sato S., Otomo M., Hirayama Y., Sato H., et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology 2008, 47:1539-1542.
34. Miller F.W., Rider L.G., Plotz P.H., Rutkove S.B., Pestronk A., Wortmann R.L., et al. Polymyositis: an overdiagnosed entity. Neurology 2004, 63:402-403.
35. Hoogendijk J.E., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion-body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
36. Cox S, Limaye V, Hill C, Blumbergs P, Roberts-Thomson P. Idiopathic inflammatory myopathies: Diagnostic criteria, classification and epidemiological features. Int J Rheum Dis 13:117-24.
37. Sultan S., Isenberg D.A. Re-classifying myositis. Rheumatology 2010, 49:831-833.
38. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F.L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007, 17:194-200.
39. Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185-190.
40. Le Roux K., Streichenberger N., Vial C., Petiot P., Feasson L., Bouhour F., et al. Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve 2007, 35:171-177.
41. Dalakas M.C. Polymyositis dermatomyositis, and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.